---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-21-056810"
form_type: "8-K"
ticker: "BDSX"
cik: "0001439725"
company_name: "BIODESIX INC"
filed_at: "2021-11-15T23:59:59+00:00"
generated_at: "2026-06-28T08:17:00.955865+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Biodesix Q3 lung diagnostic revenue up 51% YoY; launches 72-hour NGS test

## Summary
- Total revenue $6.5M; lung diagnostic revenue $4.5M (+51% YoY), services $1.5M (+133%), COVID-19 testing $0.5M (-91%).
- Gross margin 58% (up from 40% in Q2 2021); operating expenses $16.9M (+46%).
- Net loss $11.5M (+30%); includes $3.1M non-cash PPP loan forgiveness gain.
- Cash and cash equivalents $47.9M as of Sept 30, 2021.
- Launched 72-hour liquid NGS test ahead of schedule; broad US launch targeted for Q1 2022.

## SEC filing metadata
- accession: 0001564590-21-056810
- form_type: 8-K
- ticker: BDSX
- cik: 0001439725
- company_name: BIODESIX INC
- filed_at: 2021-11-15T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1439725/000156459021056810/0001564590-21-056810-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1439725/000156459021056810/bdsx-8k_20211115.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-21-056810
- JSON: https://secwatch.observer/filing/0001564590-21-056810.json
- Plain text: https://secwatch.observer/filing/0001564590-21-056810.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.